Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Marti

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Autoimmunity|November 22, 2008
Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black miceBrian J Scaglione, Erica Salerno, Kinisha Gala, et al.
Oncotarget|August 18, 2016
Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemiaChingiz Underbayev, Siddha Kasar, William Ruezinsky, et al.
Frontiers in Genetics|January 30, 2023
Genome-wide DNA methylation profiling in chronic lymphocytic leukaemiaQiuyi Zhang, Ying Gao, Shuchun Lin, et al.
Frontiers in Allergy|January 26, 2023
Towards an FDA-cleared basophil activation testOral Alpan, Richard L Wasserman, Theodore Kim, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|September 16, 2016
Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibilityLynn R Goldin, Mary L McMaster, Melissa Rotunno, et al.
Nature Communications|December 17, 2016
Evolution of multiple cell clones over a 29-year period of a CLL patientZhikun Zhao, Lynn Goldin, Shiping Liu, et al.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Autoimmunity|November 22, 2008
Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black miceBrian J Scaglione, Erica Salerno, Kinisha Gala, et al.
Oncotarget|August 18, 2016
Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemiaChingiz Underbayev, Siddha Kasar, William Ruezinsky, et al.
Frontiers in Genetics|January 30, 2023
Genome-wide DNA methylation profiling in chronic lymphocytic leukaemiaQiuyi Zhang, Ying Gao, Shuchun Lin, et al.
Frontiers in Allergy|January 26, 2023
Towards an FDA-cleared basophil activation testOral Alpan, Richard L Wasserman, Theodore Kim, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|September 16, 2016
Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibilityLynn R Goldin, Mary L McMaster, Melissa Rotunno, et al.
Nature Communications|December 17, 2016
Evolution of multiple cell clones over a 29-year period of a CLL patientZhikun Zhao, Lynn Goldin, Shiping Liu, et al.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Pageof 3